Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Whiteley GR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kaczmarczyk JA; Meso Scale Diagnostics, Rockville, MD, USA. JKaczmarczyk@meso-scale.com.; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. JKaczmarczyk@meso-scale.com., Whiteley GR; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Blonder J; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. blonderj@mail.nih.gov.
Publikováno v:
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2823, pp. 269-289.
Autor:
Sissung TM; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Barbier RH; Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Price DK; Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Plona TM; CLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Pike KM; CLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Mellott SD; CLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Baugher RN; CLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Whiteley GR; CLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Soppet DR; Genomics Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Venzon D; Biostatistics and Data Management, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA., Berman A; Office of Research Nursing in the Office of the Clinical Director, National Cancer Institutes, National Institutes of Health, Bethesda, MD 20892, USA., Rajan A; Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Giaccone G; Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Meltzer P; Genetics Branch, National Cancer Institute, Bethesda, MD 20814, USA., Figg WD; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2020 Jan 30; Vol. 21 (3). Date of Electronic Publication: 2020 Jan 30.
Autor:
Schoenherr RM; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Huang D; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Voytovich UJ; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Ivey RG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kennedy JJ; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Saul RG; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Colantonio S; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Roberts RR; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Knotts JG; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kaczmarczyk JA; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Perry C; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hewitt SM; National Cancer Institute, Bethesda, MD, USA., Bocik W; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Whiteley GR; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hiltke T; National Cancer Institute, Bethesda, MD, USA., Boja ES; National Cancer Institute, Bethesda, MD, USA., Rodriguez H; National Cancer Institute, Bethesda, MD, USA., Whiteaker JR; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Paulovich AG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. apaulovi@fredhutch.org.
Publikováno v:
Scientific data [Sci Data] 2019 Aug 29; Vol. 6 (1), pp. 160. Date of Electronic Publication: 2019 Aug 29.
Autor:
Ye X; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Luke BT; Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Wei BR; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Kaczmarczyk JA; Cancer Research Technology Program, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Loncarek J; Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Dwyer JE; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Johann DJ; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72209, USA., Saul RG; Cancer Research Technology Program, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Nissley DV; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., McCormick F; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA., Whiteley GR; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Blonder J; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Publikováno v:
Oncotarget [Oncotarget] 2018 May 29; Vol. 9 (41), pp. 26431-26452. Date of Electronic Publication: 2018 May 29 (Print Publication: 2018).
Autor:
Waters AM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Ozkan-Dagliyan I; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Vaseva AV; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA., Fer N; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Strathern LA; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Hobbs GA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Tessier-Cloutier B; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia V5Z 1L3, Canada., Gillette WK; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Bagni R; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Whiteley GR; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., Hartley JL; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA., McCormick F; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.; UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California at San Francisco (UCSF), San Francisco, CA 94143, USA., Cox AD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Houghton PJ; Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA., Huntsman DG; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia V5Z 1L3, Canada., Philips MR; Perlmutter Cancer Institute, New York University School of Medicine, New York, NY 10016, USA., Der CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. cjder@med.unc.edu.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Publikováno v:
Science signaling [Sci Signal] 2017 Sep 26; Vol. 10 (498). Date of Electronic Publication: 2017 Sep 26.